Haemonetics
company based in Braintree, Massachusetts, USA
HAE NYSE
ISIN US4050241003 SEC CIK 313143 LEI 549300ZEL6TXZS6F5F95
Follow Haemonetics
Weekly email: filings, results
Revenue, last quarter
$346.4M
+4.8% vs same quarter last year
Net income
−$117.4M
−7.1% vs same quarter last year
EPS, diluted
-
Operating cash flow
$70.9M
−39.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY26 | $1.3B | $97.3K |
| FY25 | $1.4B | $167.7K |
| FY24 | $1.3B | $117.6M |
| FY23 | $1.2B | $115.4M |
| FY22 | $993.2M | $43.4M |
| FY21 | $870.5M | $79.5M |
| FY20 | $988.5M | $76.5M |
| FY19 | $967.6M | $55M |
| FY18 | $903.9M | $45.6M |
| FY17 | $886.1M | −$26.3M |
| FY16 | $908.8M | −$55.6M |
| FY15 | $910.4M | $16.9M |
| FY14 | $938.5M | $35.1M |
| FY13 | $892M | $38.8M |
| FY12 | $727.8M | $66.9M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY26 | 59% | 11.7% | 0% |
| FY25 | 55% | 16.3% | 0% |
| FY24 | 52.8% | 12.6% | 9% |
| FY23 | 52.6% | 13.4% | 9.9% |
| FY22 | 50.9% | 8.1% | 4.4% |
| FY21 | 45.7% | 10.3% | 9.1% |
| FY20 | 49% | 10.5% | 7.7% |
| FY19 | 43.2% | 8.6% | 5.7% |
| FY18 | 45.6% | 6.2% | 5% |
| FY17 | 42.7% | −2.2% | −3% |
| FY16 | 44.7% | −4.8% | −6.1% |
| FY15 | 47.7% | 4.5% | 1.9% |
| FY14 | 49.9% | 4.9% | 3.7% |
| FY13 | 48% | 6.3% | 4.3% |
| FY12 | 50.7% | 12.2% | 9.2% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY26 | $260.4M |
| FY25 | $142.4M |
| FY24 | $143.6M |
| FY23 | $81.7M |
| FY22 | $75.8M |
| FY21 | $71.8M |
| FY20 | $109.5M |
| FY19 | $40.3M |
| FY18 | $145.6M |
| FY17 | $83.6M |
| FY16 | $19.5M |
| FY15 | $5M |
| FY14 | $65.9M |
| FY13 | $22.9M |
| FY12 | $62.1M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY26 | $175M |
| FY25 | $225M |
| FY24 | $0 |
| FY23 | $75M |
| FY22 | $0 |
| FY21 | $0 |
| FY20 | $175M |
| FY19 | $160M |
| FY18 | $100M |
| FY17 | $0 |
| FY16 | $61M |
| FY15 | $39M |
| FY14 | $0 |
| FY13 | $50M |
| FY12 | $50M |
- Haemonetics
- Healthcare median
Show the numbers
| Year | Haemonetics | Healthcare median |
|---|---|---|
| FY26 | 0% | −11.1% |
| FY25 | 0% | −30.6% |
| FY24 | 9% | −47% |
| FY23 | 9.9% | −58% |
| FY22 | 4.4% | −80.4% |
| FY21 | 9.1% | −71.9% |
| FY20 | 7.7% | −62.2% |
| FY19 | 5.7% | −46.3% |
| FY18 | 5% | −49.6% |
| FY17 | −3% | −45.9% |
| FY16 | −6.1% | −36% |
| FY15 | 1.9% | −38.4% |
| FY14 | 3.7% | −35.5% |
| FY13 | 4.3% | −37.1% |
| FY12 | 9.2% | −29.1% |